Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus.
BACKGROUND
Epidemiological and basic science evidence suggests that magnesium sulphate before birth may be neuroprotective for the fetus.


OBJECTIVE
To assess the effectiveness and safety of magnesium sulphate as a neuroprotective agent when given to women considered at risk of preterm birth.


METHODS
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (October 2006), CENTRAL (The Cochrane Library 2006, Issue 3), MEDLINE (1966 to October 2006), EMBASE (1980 to October 2006), Current Contents (1992 to October 2006), references of retrieved articles, and abstracts submitted to the Society for Pediatric Research (1996 to 2006).


METHODS
Randomised controlled trials of antenatal magnesium sulphate therapy given to women threatening or likely to give birth at less than 37 weeks' gestational age.


METHODS
We independently extracted data regarding clinical outcomes including paediatric mortality, neurologic outcome of survivors (including blindness, deafness, cerebral palsy and major neurosensory disability), and maternal complications and side-effects. At least two authors assessed trial eligibility and quality, and extracted data.


RESULTS
Four trials (3701 babies) were eligible for this review. No statistically significant effect of antenatal magnesium sulphate therapy was detected on any major paediatric outcome, including mortality (e.g., paediatric mortality relative risk (RR) 0.97; 95% confidence interval (CI) 0.74 to 1.28; four trials; 3701 infants), and neurological outcomes in the first few years of life, including cerebral palsy (RR 0.77; 95% CI 0.56 to 1.06; four trials; 3701 infants), neurological impairments or disabilities. There were also no significant effects of antenatal magnesium therapy on combined rates of mortality with neurologic outcomes. There was a significant reduction in the rate of substantial gross motor dysfunction (RR 0.56; 95% CI 0.33 to 0.97; two trials; 2848 infants). There were higher rates of minor maternal side-effects in the magnesium groups, but no significant effects on major maternal complications.


CONCLUSIONS
The role for antenatal magnesium sulphate therapy as a neuroprotective agent for the preterm fetus is not yet established. Given the possible beneficial effects of magnesium sulphate on gross motor function in early childhood, outcomes later in childhood should be evaluated to determine the presence or absence of later potentially important neurologic effects, particularly on motor or cognitive function. Further information will be available from one of the studies where outcomes are being evaluated again at eight to nine years of age, and from another trial currently in progress.
Doyle
L W
LW
University of Melbourne, Department of Obstetrics and Gynaecology, The Royal Women's Hospital, 132 Grattan Street, Melbourne, Victoria, Australia, 3053. lwd@unimelb.edu.au
Crowther
C A
CA
Middleton
P
P
Marret
S
S
D002493:Central Nervous System Diseases / Q000517:prevention & control*; D002547:Cerebral Palsy / Q000401:mortality / Q000517:prevention & control; D005260:Female; D005313:Fetal Death / Q000517:prevention & control*; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000401:mortality / Q000517:prevention & control; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D011247:Pregnancy; D047928:Premature Birth; D011295:Prenatal Care; D016032:Randomized Controlled Trials as Topic
D018696:Neuroprotective Agents; D008278:Magnesium Sulfate